Santos-Beneit, F., Rakeviius, V., Skeberdis, V
The method of any one of embodiments 39-45, wherein the composition comprises from about 50% to about 99.99% by weight of the triglycerides, about 55% to about 99.99% by weight of the triglycerides, about 60% to about 99.99% by weight of the triglycerides, about 65% to about 99.99% by weight of the triglycerides, about 70% to about 99.99% by weight of the triglycerides, about 75% to about 99.99% by weight of the triglycerides, about 80% to about 99.99% by weight of the triglycerides, about 85% to about 99.99% by weight of the triglycerides, about 90% to about 99.99% by weight of the triglycerides, or about 95% to about 99.99% by weight of the triglycerides
The long-acting formulation means that cagrilintide maintains therapeutic levels for extended periods, making it suitable for weekly administration protocols in research settings
doi: 10.1016/j.cell.2022.06.003 36